Login to Pancreatic Cancer UK

Parliamentary news

Here you can read about how pancreatic cancer is being addressed in the Westminster Parliament and in other elected bodies around the UK. These are just summaries so please follow the links for more details.

For information on previous years' activities, see the foot of the page.

2015

2nd December: Mohammed Ashgar AM asked what plans the Welsh Government had to improve services for pancreatic cancer patients in Wales. 

23rd November: Jim Shannon MP tabled an Early Day Motion commending research by Ulster University into a new minimaly invasive treatment for pancreatic cancer. 

19th November: A debate was held in the House of Commons on the new Cancer Strategy, during which Nic Dakin MP, Justin Madders MP and Mark Durkan raised the issue of pancreatic cancer. 

17th November: Nic Dakin MP asked what implications the removal of Abraxane and other cancer drugs from the Cancer Drugs Fund list would have on life sciences. 

17th November: We joined up with Pancreatic Cancer Scotland to hold an evening reception at the Scottish Parliament as part of our parliamentary activities surrounding Pancreatic Cancer Awareness Month. 

12th November: David Melding AM asked what steps the Welsh Government was taking to shorten waiting times for diagnostic tests for people suspected of having pancreatic cancer. He also questioned what the Government was doing to ensure the rapid referral of pancreatic cancer patients from GPs to pancreatic cancer specialists. 

4th November: Mick Antoniw AM asked what action the Welsh Government was taking to tackle pancreatic cancer in Wales before the next Assembly election. Responding Health and Social Services Minister Mark Drakeford noted the calls laid out in Pancreatic Cancer UK's Diagnosis Manifesto for Wales, adding that they correlated with the Welsh Governments Cancer Delivery Plan. 

3rd November: Janet Haworth AM questioned the First Minister about the use on Decision Aid Tools and GP access to diagnostic tests

3rd November: Lynne Neagle AM asked First Minister Carwyn Jones what steps he was taking to raise awareness of pancreatic cancer

3rd November: Jo-Anne Dobson AM asked how the Government would address the findings of Pancreatic Cancer UK's Diagnosis Manifesto for Northern Ireland

2nd & 3rd November: We held events at both the Northern Ireland Assembly and the National Assembly for Wales as part of Pancreatic Cancer Awareness Month. 

27th October: We hosted a drop-in event in Westminster, during which 70 MPs joined us to learn more about pancreatic cancer and what activities Pancreatic Cancer UK was organising as part of Pancreatic Cancer Awareness Month. 

26th October: Nic Dakin MP tabled an Early Day Motion recognising Pancreatic Cancer Awareness Month. 

26th October: Lynne Neagle AM tabled a Statement of Opinion  on Pancreatic Cancer Awareness Month and welcoming the Purple Lights for Hope initiative.           

26th October: Clare Adamson MSP tabled a Motion noting that November is Pancreatic Cancer Awareness and welcoming work to improve pancreatic cancer awareness, diagnosis, treatment and care across Scotland. 

26th October: Thomas Buchanan MLA tabled a Motion on Pancreatic Cancer Awareness Month, congratulating pancreatic cancer charities for their planned awareness raising activities. 

20th October: Jim Shannon MP raised a debate in Parliament on access to cancer drugs, during which Nic Dakin MP, Nick Thomas-Symonds MP, Mark Durkan MP and Oliver Heald MP discussed pancreatic cancer and Araxane. 

20th October: Jim Shannon MP asked what steps were being taking to introduce earlier forms of diagnosis for pancreatic cancer on the NHS. 

9th October: Rebecca Long-Bailey MP asked what assessment had been made of the potential effect the removal of Abraxane from the Cancer Drugs Fund would have on survival rates for pancreatic cancer.  

9th September: Richard Benyon MP questioned what mechanisms are in place to assess whether the dietary and other standards set out in the service specifications for pancreatic cancer are being met. 

8th September: Rosie Cooper MP asked what assessment had been made of the level of provision of pancreatic cancer treatment on the NHS; what the reasons were for the most recent NHS England review of Abraxane's availability on the Cancer Drugs Fund;and what steps the what steps the Minister was taking to ensure that expert clinicans are consulated when assessing new treatments for pancreatic cancer.

21st July: Nic Dakin MP presented to Parliament our petition, calling for the pancreatic cancer drug Abraxane to be retained on the Cancer Drugs Fund list. 

14th July: Lord Aberdare asked what assessment had been made of the number and the proportion of pancreatic cancer patients whose diagnosis is made following an emergency admission to hospital

10th July: Darren Millar AM received answers from the Welsh Health Minister about treatment waiting times for pancreatic cancer and how many times pancreatic cancer patients have to visit their GP before being diagnosed. The answers can be viewed on the Welsh Assembly website.  

9th July: Richard Benyon MP received responses to questions on progress made in establishing trials for pancreatic cancer patients using stereotactic ablative radiotherapy; steps being taken to ensure ensure new treatment options for pancreatic cancer are made available on the NHS at the earliest opportunity; action being taken to ensure that all pancreatic cancer patients have access to dietetic treatment, advice and support; and when the National Institute for Health and Care Excellence would commence work on the development of clinical guidance for pancreatic cancer

9th July: Lord Aberdare received a response to questions on  steps the Government was taking to ensure all pancreatic cancer patients have access to a Clinical Nurse Specialist and plans to increase the capacity of imaging services available to pancreatic cancer patients across the NHS, including computerised tomography scans.

8th July: Margaret Ritche MP asked what assessment had been made of the potential effect of the new NICE Referral Guidelines for Suspected Cancer on early diagnosis and the number of patients referred for CT scans each year. 

7th July: Mark Durkan MP asked the Minister what assessment had been made of a potential link between a diagnosis of diabetes and increased risk of pancreatic cancer

7th July: Nic Dakin MP asked the Health Minister what estimate had been made of the proportion of newly-diagnosed pancreatic cancer patients who start treatment within 62 days of diagnosis.

2nd July: Stuart Andrew MP received responses to two questions on pancreatic cancer research. He asked what assessment had been made of the adequacy of funding for pancreatic cancer research over the last five years and what steps were being taken to improve the quality and quantity of research into pancreatic cancer.

2nd July: Nick Thomas-Symonds MP asked the Minister what discussions he had held with Health Ministers in the devolved administrations on increasing research into pancreatic cancer across the UK. He also asked what comparative assessment had been made of variation in the survival rates of pancreatic cancer patients living in the UK, Europe and the rest of the world.

2nd July: Nic Dakin MP received an answer to questions on what assessment had been made of the average number of times pancreatic cancer patients visited their GP before being referred to hospital and what steps were being taken to ensure earlier diagnosis of pancreatic cancer. He also asked what assessment had been made of variations in survival rates for pancreatic cancer across different regions and Clinical Commissioning Groups.  

2nd July: Mark Durkan MP asked the Public Health Minister what steps were being taken to improve public awareness of pancreatic cancer and what recent discussions she had held with Health Ministers in the devolved administrations on improving awareness of pancreatic cancer across the UK. 

10th June: Nic Dakin MP asked whether steps would be taken to ensure treatments for pancreatic cancer on the Cancer Drugs Fund list continued to be made available to patients on the NHS. 

26th March: Peter Weir AM asked the Northern Ireland Health Minister what actions were being taken to increase early diagnosis of pancreatic cancer.

26th March: Mrs Brenda Hale AM asked the NI Health Minister how many pancreatic cancer patients were referred to a pain clinic over the past twelve months. She also asked what was being done to increase the level of research funding into pancreatic cancer.

24th March: Fearghal McKinney AM asked the NI health Minister about the diagnosis and treatment of pancreatic cancer.

23rd March: Mrs Jo-Anne Dobson AM asked the NI Health Minister what steps were being taken to develop a screening test for pancreatic cancer, and what plans were in place to increase the number of pancreatic cancer specialist nurses in Northern Ireland.

23rd February: Tom Buchanan AM asked the NI Health Minister to confirm the location of the pancreatic cancer centre in Northern Ireland, and whether pancreatic cancer would be included as part of the Be Cancer Aware public information camapign in Northern Ireland.

23rd February: Lord Turnberg received replies from the Health Minister in the Lords to two questions: one on what the government was doing to improve pancreatic cancer survival rates and one about what was being done to ensure pancreatic cancer patients had access to new treatments. The two questions received one long answer, which can be found here.

20th January: Ian Swales MP received an answer from the Health Minister about the amount of money spent on pancreatic cancer drugs by the Cancer Drugs Fund (CDF).

15th January: Nic Dakin MP secured an Adjournment Debate on Pancreatic Cancer outcomes which covered a range of issues such as access to new drugs, awareness of symptoms, new treatments and refrral pathways. Eric Ollerenshaw MP also spoke in the debate, which was replied to by Health Minister Jane Ellison MP. The debate can be read in full here.

6th January: Andrew Rosindell MP asked the Minister what effect a proposed new EU Regulation on Data Protection might have on pancreatic cancer research.